A marked increase in HDL notwithstanding, the cholesterol ester transfer protein (CETP) inhibitor torcetrapib was associated with an increase in all-cause mortality in the ILLUMINATE trial. As underlying mechanisms remain elusive, the present study was designed to delineate potential off-target effects of torcetrapib.
Introduction
The plasma levels of high-density lipoprotein (HDL) cholesterol are inversely related to cardiovascular risk. 1 -3 Currently available HDL-raising therapies are associated with undesirable side effects, limited efficacy, or have not yet been shown to improve morbidity and mortality on top of statins in clinical outcome trials. 4 -6 A novel pharmacological target for raising circulating HDL-C levels is the cholesterol ester transfer protein (CETP), an enzyme involved in the physiological process of reverse cholesterol transport in humans, by which excess cholesterol is removed from peripheral tissues, and then returned to the liver for secretion into the bile. Conceptually, inhibition of CETP thus provides an attractive therapeutic target. 7 Indeed, three pharmacological small-molecule inhibitors of CETP, i.e. dalcetrapib (JTT-705; Roche), anacetrapib (Merck), and torcetrapib (Pfizer), have been developed. The molecules effectively raise HDL-C by 60-100% in humans either when used as a monotherapy or in combination with statins. † B.S. and M.H. contributed equally to this work.
Surprisingly and in spite of a marked increase in HDL-C and a reduction in LDL-C levels, an unexpected increase in all-cause mortality, including cardiovascular and non-cardiovascular events, was observed in patients treated with torcetrapib in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) study. 8 Furthermore, three large imaging trials using coronary intravascular ultrasound and carotid intima-media thickness demonstrated a lack of efficacy of torcetrapib on coronary atheroma burden or carotid intima-media thickness, respectively, again in spite a marked increase in HDL levels. 9 -11 The molecular mechanisms for this excess in cardiovascular morbidity and mortality and lack of anti-atherosclerotic efficacy remain still elusive. It is of note that the use of torcetrapib was associated with an increase in blood pressure (BP) in ILLUMINATE as well as in clinical trials of the early development phase. 9 -13 As the potent CETP inhibitors dalcetrapib and anacetrapib are devoid of such pressor effects, 14 -17 the BP elevation associated with torcetrapib may represent an off-target effect specific for this molecule. Importantly, in the ILLUMINATE study, a moderate decrease in potassium and slight increase in sodium and bicarbonate was observed in the torcetrapib group, suggesting a potential mineralocorticoid effect of torcetrapib. 8 Thus, the aim of the present study was to delineate underlying potential off-target effect(s) of torcetrapib in experimental hypertension. As endothelial function may be an obvious target of the compound, we investigated specifically, whether and to what degree torcetrapib impacts on this well-established surrogate for cardiovascular risk.
Methods Animals
Male spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats, 16-20 weeks old, mean weight 320 g, were purchased from Charles River Laboratories (Research Models and Services, Germany GmbH). Animals were fed a normal chow diet and had ad libitum access to food and water, maintained at 248C under a 12 h light/dark cycle. Torcetrapib (CP-529414 Spray-dried dispersion, LOT ID FP-04-069, kindly provided by Pfizer Inc., Groton, CT, USA) or placebo was given as a suspension in 0.5% methyl cellulose in a final concentration 100 mg/kg/day p.o. (oral gavage), for a total duration of 3 weeks. Dosage of torcetrapib was adjusted for body weight and calculated on a daily basis. In addition, animals were co-treated with the endothelin (ET)-receptor antagonist bosentan 100 mg/kg/day (Actelion Pharmaceuticals Ltd, Switzerland) together with torcetrapib. Systolic BP and heart rate were measured by tail-cuff method (model LE 5002, Storage Pressure Meter, Letica, Spain) after intensive training of the animals.
Study design and experimental protocols fully complied with the guidelines for research animal use by the American Heart Association and were approved by the institutional animal care committee (Licence Nr. 17/2008, Kommission für Tierversuche des Kantons Zürich, Switzerland).
Tissue harvesting and organ chamber experiments
At the end of the 21-day treatment, animals were first anaesthetized using pentobarbital (50 mg/kg i.p.) and sacrificed by blood exsanguinations. Blood was drawn into Li-Heparin-coated vacutainers (Vacutainer w Heparin Tubes, Additive Lithium Heparin (68 USP), BD) and plasma was isolated. Aorta was removed and placed in cold (48C) modified Krebs -Ringer bicarbonate solution.
The aorta was cleaned from connective tissue and cut into rings of 3 mm length. The remaining aortic tissue was snap frozen in liquid nitrogen for further analysis. Aortic rings were placed in an organ bath for isometric tension recording as described elsewhere. 18 Shortly after 60 min of an equilibration, the rings were progressively stretched to their optimal passive tension (3 g). Rings were preconstricted with norepinephrine (NE, 70% of 100 mM KCl) and relaxations to acetylcholine ( 
Endothelin-1 determination
Tissue ET-1 level was determined as described previously. 21 Briefly, tissue was hydrolyzed in 0.1 M acetic acid at 808C, and then thoroughly homogenized using a polytron homogenizer. After centrifugation, extraction was performed using a standard peptide extraction procedure, by adsorption on prewashed Sep-Pak Vac C18 (500 mg) cartridges (Millipore). The ET-1 level was determined using radioimmunoassay and the recording was done using a g counter and the radioimmunoassay data processed using machine software (Canberra Packard).
Immunohistochemistry
Prior to histological analysis, samples were embedded in Tissue-Tek w O.C.T. TM compound (Sakura Finetek Europe, Zoeterwoude, the Netherlands), frozen on dry ice and stored at 2808C. Cryosections of rat aortas (7 mm) were fixed with freshly prepared 4% paraformaldehyde on SuperFrost w (SuperFrost, Braunschweig, Germany) slides. Endogenous peroxidase activity was blocked by dipping the slides for 5 min in a 3% H 2 O 2 -methanol solution. Slides were further incubated in a humid chamber at 48C overnight with or without first antibody against rat ET A and ET B receptors (1:10 dilution; Alomone Labs Ltd, Jerusalem, Israel). After washing in phosphate-buffered saline, affinitypurified biotin-conjugated goat anti-rabbit antibody (Dako, Glostrup, Denmark) was applied for 60 min at room temperature in a humid chamber. Slides were then exposed to avidin-biotin -horseradish peroxidase complex prepared from the reagents supplied by Dako (Glostrup, Denmark, Cat. no. KO355) during 45 min. Bound peroxidase was detected after 3 min incubation at room temperature with 3,3
′ -diaminobenzidine substrate (Sigma, St Louis, MO, USA). Sections were finally counterstained briefly with haematoxylin (Merck, Darmstatt) and mounted in Aquatex (Merck).
Intensity was scored by an independent observer in at least three different samples and unaware of the groups and treatments. In order to evaluate the integrity of the endothelium and vascular smooth muscle layers, some samples were stained with von Willebrand factor (Dako) and smooth muscle actin (Dako). To evaluate possible background reactions, procedures were also performed in sections incubated with the provided control peptide antigen (Alomone Labs Ltd.) in excess.
Plasma electrolytes and lipids
Plasma electrolytes (Na + , K + , and Cl 2 ) and plasma lipids (HDL-C, LDL-C, and total cholesterol) were determined using standard enzymatic method on an automated analyser (Hitachi 912, Roche Diagnostics AG system, Rotkreuz, Switzerland).
Plasma aldosterone, renin, and angiotensin II levels
Plasma aldosterone, renin, and angiotensin levels were determined using commercially available ELISA kits (aldosterone: Alpha Diagnostic International, San Antonio, TX, USA; renin and angiotensin II: Cusabio Biotech Co., Ltd, Newark, DE, USA).
Cell culture
Human aortic endothelial cells (HAECs) were obtained from Clonetics w . In 60-mm culture dishes, HAECs were grown in endothelial basal medium (Clonetics w ), in a humidified atmosphere (378C, 95% air /5% CO 2 ). Media was supplemented with 10% Foetal calf serum and EGM TM -2 SingleQuots w (Cat. no. CC-4176, Clonetics w ). After confluence, cells were rendered quiescent by incubation in medium with 0.5% serum for 24 h and then stimulated with vehicle methanol and torcetrapib pure drug (CP-529414, Lot ID 052301-001-21, Pfizer Inc.) for additional 24 h. At 24 h time point, 1000 mL media were removed from each dish for the cell viability assay using Cytotoxicity Detection Kit (LDH, Cat. no. 11 644 793 001, Roche). Cells were lysed in ice cold lysis buffer as described above. Lysates were frozen at 2808C until Western blot analysis.
Measurement of endothelial cell nitric oxide production by electron spin resonance spectroscopy
The effects of torcetrapib (1000 nM; 24 h at 378C) on endothelial NO production (HAECs; passage number 4 -6; Clonetics w ) was examined by electron spin resonance (ESR) spectroscopy using the spin-probe colloid Fe(DETC) 2 (Noxygen, Elzach, Germany), as described previously. 22 In brief, ESR spectra of samples frozen in liquid nitrogen Measurement of superoxide production in rat aorta by electron spin resonance spectroscopy
Superoxide production was determined in rat descending aorta sections by ESR spectroscopy using the spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-1-pyrrolidine and an e-scan ESR spectrometer (Bruker BioSpin). Time-dependent formation of superoxide was analysed using the following instrumental settings: centre field 1.99 g, microwave power 20 mW, modulation amplitude 2 G, sweep time 60 s, field sweep 60 G. The intensity of ESR spectra was quantified after calibration of ESR signals with the free radical 3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy. The intensity values were divided by the dry weight of aorta sections.
Calculations and statistical analysis
Data are presented as mean + SEM. Contraction or relaxation (as per cent pre-contraction in rings pre-contracted to 70 -80% of contraction induced by potassium chloride, 100 mM), negative logarithm of the concentration causing half-maximal relaxation or contraction (EC 50 Torcetrapib impairs endothelial function in hypertension value), and area under the curve were determined for each individual dose -response curve by non-linear regression analysis using GraphPad Prism 5.0 software for Windows (GraphPad Software, San Diego, CA, USA, www.graphpad.com). For comparing two groups, an unpaired Student's t-test was applied and, for multiple comparisons, the one-way ANOVA was used, followed by unpaired t-test for two-group-comparisons, when the ANOVA was significant. All statistical tests used were two sided. A value of P , 0.05 was considered significant.
Results
Animal characteristics and general data Systolic blood pressure Body weight and systolic BP were monitored throughout the entire duration of the study ( Table 1) . Systolic BP was elevated for 3 days after the start of torcetrapib administration in SHRs (P , 0.05), but not in WKY rats. However, BP returned to baseline after the third day and remained at initial levels despite continuous drug administration ( Figure 1A ). No change in BP was observed in WKY rats ( Figure 1B ).
Torcetrapib plasma levels
Plasma levels of torcetrapib were determined by UPLC-ESI-MS. The values averaged 0.648 and 0.820 mg/mL, respectively, in SHR-T and WKY-T ( Table 2) .
Plasma electrolytes and lipids
Plasma levels of K + and Cl 2 were comparable for all groups. There was a tendency for lower Na + levels in SHR-T (P ¼ 0.059 vs.
SHR-P). No difference was detectable in WKY rats ( Table 2) . Plasma lipid levels remained unchanged ( Table 2) .
Activity of the endothelial L-arigine/nitric oxide pathway
Expression of endothelial nitric oxide synthase, VCAM-1, and ICAM-1 in cultured human aortic endothelial cells Torcetrapib pure drug was used in cultured HAECs to investigate changes in NO bioavailability in vitro. The cell viability assay showed no torcetrapib-induced cellular toxicity (10-3000 nM, Figure 2A) . A marked down-regulation of total eNOS protein in HAECs treated with torcetrapib was observed (227.16, 235.35, 237.09, and 237.74%, for 100, 500, 1000, and 3000 nM torcetrapib, respectively; P , 0.05, for all torcetrapib concentrations vs. vehicle-treated cells) ( Figure 2B ). Both VCAM-1 and ICAM-1 were not differentially regulated in HAECs treated with torcetrapib vs. vehicle-treated HAECs, both at RNA and protein level (see Supplementary material online, Figure S6 ).
Nitric oxide release in cultured human aortic endothelial cells
In HAECs treated with torcetrapib, a marked reduction in NO release was observed as assessed by ESR spectroscopy (227.06%, P , 0.01 vs. vehicle-treated cells) ( Figure 2C ). gene expression was found in torcetrapib-treated WKY rats (P ¼ 0.5206 vs. placebo-treated WKY rats) ( Figure 3C ). Both VCAM-1 and ICAM-1 were not differentially expressed in aortas of SHR-T and SHR-P, both at RNA and protein level (see Supplementary material online, Figure S7 ). Furthermore, iNOS expression was not changed in torcetrapib-treated SHR vs. placebotreated SHR (see Supplementary material online, Figure S8 ).
Endothelium-dependent and endothelium-independent relaxation Torcetrapib induced impairment of endothelium-dependent relaxation to ACh in isolated aortic rings from SHR-T pre-contracted with NE (P , 0.0002 for 10 29 M ACh, and P , 0.0001 for 10 28 , 10 27 , 10 26 , and 10 25 M ACh vs. SHR-P, Figure 4 ). Dose-response curves were used to determine EC 50 value (2log[M]) between torcetrapib-and placebo-treated SHRs which were 7.736 and 7.989, for SHR-T and SHR-P, respectively (P ¼ 0.0069). The area under the curve (AUC) was reduced in SHR-T (220.57%, P , 0.0001 vs. SHR-P, Table 1 ) as well as the maximal response (211.83%, P , 0.0001 vs. SHR-P). No difference in ACh-induced endothelium-dependent relaxation was observed between the rings isolated from torcetrapib-treated and placebo-treated WKY rats, respectively ( Figure 4) . Endothelium-independent vasorelaxation to SNP (10 210 -10 25 M) did not reveal any difference between SHR-T and SHR-P (data not shown).
Generation of reactive oxygen species
To investigate the effects of tocretrapib on oxidative stress in vivo, the generation of reactive oxygen species (ROS) was measured in aortas of torcetrapib-treated (SHR-T) and placebo SHR (SHR-P) using ESR spectroscopy. The aortas of SHR treated with torcetrapib showed an increase in ROS production as assessed by ESR spectroscopy (+83.5%, P , 0.05 vs. SHR-P) ( Figure 5 ). 
Activity of the vascular endothelin system
Vascular reactivity to endothelin-1 Endothelin-1-induced contractions (10 28 and 10 27 M) of isolated aortic rings obtained from SHR-T were increased when compared with those obtained from SHR-P (P ¼ 0.0279 and 0.0243, respectively) ( Figure 6 ). The AUC was increased in SHR-T (+33%, P , 0.05 vs. SHR-P, Table 1 ). The EC 50 value (2log[M]) of aortic rings from SHR-T and EC 50 value of SHR-P were calculated and averaged 7.998 and 7.965, respectively ( Table 1) . Vascular reactivity to ET-1 in WKY rats remained unchanged after torcetrapib treatment ( Figure 6 ).
Aortic endothelin tissue levels during torcetrapib treatment
Tissue content of ET-1 in the aortas of SHR-T was increased (+49.56%, P ¼ 0.0154 vs. SHR-P) ( Figure 7) . Endothelin-1 tissue levels in WKY-T did not significantly differ from those obtained in WKY-P (P ¼ 0.2764).
Aortic endothelin receptor expression during torcetrapib treatment The ET A gene expression level showed only a tendency for a higher expression, whereas ET B gene expression tended to be decreased in SHR-T when compared with SHR-P, as measured by RT-PCR, but this difference was not statistically significant (data not shown).
Immunohistochemistry of endothelin receptors
Staining intensity of all samples was evaluated based on two independent sections. Endothelin receptor A staining was more pronounced in the endothelium, neo-intima and tunica media of SHR-T when compared with SHR-P (see Supplementary material online, Figure S1A and B). Endothelin receptor B exhibited equally pronounced staining in both the endothelium and neointima layers of SHR-T when compared with SHR-P (see Supplementary material online, Figure S2A and B). All controls, either achieved by incubation with the specific control peptide, or using normal controls analysed without primary antibodies, were negative (see Supplementary material online, Figures S1C and S2C) . von Willebrand factor-staining and smooth muscle a-actin-staining did not differ between SHR-T and SHR-P (data not shown). In some sections, we observed background at the edge of disrupted adventia which we considered insignificant taking into consideration the small size of these samples. The analysis of the staining intensities in endothelium cells and vascular smooth muscle cells (VSMCs) for ET A and ET B receptors Figure 4 Endothelium-dependent relaxation to acetylcholine in isolated aortic rings pre-contracted with norepinephrine obtained from spontaneously hypertensive rats and WistarKyoto rats. Acetylcholine-induced vasorelaxation was impaired in aortas of torcetrapib-treated spontaneously hypertensive rats (SHR-T) in comparison with placebo-treated spontaneously hypertensive rats (SHR-P), (*P , 0.0001 for SHR-T vs. SHR-P) and in SHR-P vs. WKY-P ( § P ¼ 0.01). Figure 5 Effect of torcetrapib on the generation of reactive oxygen species in aortas of spontaneously hypertensive rats treated with torcetrapib (SHR-T) when compared with placebo spontaneously hypertensive rats (SHR-P). Reactive oxygen species formation was increased in SHR-T (P ¼ 0.0411 vs. SHR-P). Figure 6 Dose-response curve to endothelin-1 in quiescent isolated aortic rings obtained from spontaneously hypertensive rats and Wistar-Kyoto rats. Endothelin-1-induced vasoconstriction of isolated aortic rings obtained from torcetrapib-treated spontaneously hypertensive rats (SHR-T) was increased compared with those obtained from placebo-treated spontaneously hypertensive rats (SHR-P), P , 0.05. No change was observed between torcetrapib-treated Wistar-Kyoto rats and placebotreated Wistar -Kyoto rats.
Torcetrapib impairs endothelial function in hypertension was performed using analySIS w software (Soft Imaging System, GmbH, Münich, Germany). No difference in the receptors' density in either endothelium or VSMCs was found for ET A or ET B receptors (see Supplementary material online, Figure S3A , B, and C).
Effects of endothelin receptor blockade
Chronic endothelin A/B-blockade and endothelium-dependent relaxation Co-administration of bosentan on top of torcetrapib (SHR-T/B) for 3 weeks restored endothelium-dependent relaxations in SHR-T (P , 0.01 vs. SHR-T/B) (Figure 8) . The EC 50 values (2log[M]) of SHR-T, SHR-P, and SHR-T/B were: 7.903, 8.126, and 7.949, respectively (P , 0.001 SHR-T vs. SHR-P). With bosentan, the area under the curve was increased (+11.63%, P , 0.05 vs. SHR-T, Table 3 ). Furthermore, maximal relaxation to ACh increased as well with bosentan ( Table 3) .
Endothelin A and B receptors' antagonism and endothelin-1-induced contraction Pre-treatment with the selective ET A receptor antagonist, BQ-123, did not change ET-1-induced contractions of aortic rings. In particular, no difference between SHR-T and SHR-P was observed. After pre-incubation with the selective ET B receptor antagonist, BQ-788, ET-1 induced contraction in SHR-T rings remained unchanged, while rings from SHR-P showed a trend in diminished responses to ET-1 at 10 28 M (see Supplementary material online, Figure S4A and B).
Activity of the renin -angiotensin -aldosterone system Plasma aldosterone was increased in SHR-T (+33.72%, P ¼ 0.0172 vs. SHR-P, see Supplementary material online, Figure S5C ), but remained unchanged within the WKY groups (data not shown). A higher trend in plasma renin activity was found in SHR-T when compared with SHR-P, but not statistically significant. No difference in angiotensin II was found between SHR-T and SHR-P (see Supplementary material online, Figure S5A and B).
Discussion
This study demonstrates that the CETP inhibitor torcetrapib induces a sustained and marked impairment of endothelial function, decreases eNOS mRNA and protein as well as NO release, stimulates aldosterone secretion as well as vascular ROS and ET production. The increased cardiovascular events in the ILLUMINATE trial suggested potential off-target effects of torcetrapib. 8 Indeed, BP elevation was paralleled by an increase in plasma aldosterone, bicarbonate and sodium as well as a reduction in plasma potassium were observed in ILLUMINATE trial. 8 Since endothelium-derived NO plays a crucial role in the maintenance of endothelial and vascular function 23 and decreased NO production has been implicated in the pathogenesis and clinical course of all known cardiovascular diseases and is associated with future risk of adverse cardiovascular events, 24 -26 the effects of torcetrapib on endothelial function in the aorta of SHRs and WKY rats were investigated. SHR treated with torcetrapib showed a marked impairment in ACh-induced endothelial-dependent relaxations, which may represent a clinically relevant mechanism. Interestingly, torcetrapib also down-regulated eNOS mRNA and protein expression in SHR aortas in vivo and decreased direct NO release in HAECs in vitro, indicating an inhibition of eNOS expression as well as inactivation of NO by torcetrapib. Intriguingly, torcetrapib stimulated the vascular production of reactive oxygen species in SHR-T. Since the link between increased oxidative stress and reduced bioavailability of NO has been well established, 27 ,28 the present results indicate that oxidative stress accounts in parts for the impairment of endothelial function induced by torcetrapib. Interestingly, torcetrapib increased both vascular reactivity to ET-1 and aortic ET-1 tissue, indicating an activation of the vascular ET system by torcetrapib in SHR. Endothelin-1, a potent endothelial vasoconstrictor peptide formed by endothelial cells, 29 impacts on salt and water homeostasis and stimulates the reninangiotensin-aldosterone system and plays a pivotal role in vascular remodelling in experimental and human hypertension. 30, 31 To further delineate the mechanisms of ET-1-induced changes on endothelium-dependent vasorelaxation in SHR-T, torcetrapib was administered to SHR and, in parallel, co-administered the ET A/B -receptor antagonist bosentan. Of note, chronic ET A/B -receptor blockade normalized endothelium-dependent relaxations, indicating that the stimulation of ET-1 is crucially involved in endothelial dysfunction induced by torcetrapib. 32 Indeed, NO and ET-1 interact with each other both at their site of production in endothelial cells 29 as well as at their site of action, i.e. in smooth muscle cells. 33 Hence it is likely that ET-1 down-regulates eNOS expression and stimulates ROS and in turn reduces NO bioavailability and endothelium-dependent relaxations.
Endothelin-1 modulates biological responses through at least two distinct types of receptors, i.e. ET A and ET B receptors. Endothelin A receptors are predominantly located on VSMCs, 34, 35 whereas ET B receptors are expressed both on VSMCs and on endothelial cells. 36 -38 To delineate a possible role of an up-regulation of ET-1 receptors in the observed increased contractile response to ET-1 in SHR-T, aortas obtained from SHR-T and SHR-P were pre-treated with the selective antagonists ET A and ET B receptors BQ-123 and BQ-788, respectively. However, these experiments revealed no difference of ET-1-induced contraction between SHR-T and SHR-P, suggesting a similar contribution of both receptors to ET-1-induced contraction both in the presence and in the absence of torcetrapib. 39 and inhibition of these channels blunts the response to the peptide in rodents 40 and in humans. 41 The increase in ET-1 tissue levels in SHR-T was paralleled by an increase in plasma aldosterone, but not renin or angiotension II levels pointing towards a direct and specific activation of the mineralcorticoid axis by ET-1. Indeed, ET-1 is a potent secretagogue of aldosterone within adrenal glands. 42 -44 The present study supports and extends recent findings by Forrest et al., 45 as we here demonstrate a transient BP and concomitant and sustained increase in plasma aldosterone after torcetrapib treatment. As BP returned to baseline, the latter phenomenon suggests an aldosterone escape at the level of the kidney and/or resistance vessels. The impairment of endothelial function is likely to represent an off-target effect of torcetrapib and unrelated to CETP inhibition, as rodents such as the rat are lacking CETP 46 and lipids remained unchanged under the conditions of the present study. Conversely, in humans, HDL increases the eNOS protein expression thereby off-setting LDL-induced inhibition of eNOS expression in dyslipidaemia and intravenous administration of reconstituted HDL into the human forearm circulation restored ACh-induced endothelial function and flow-mediated vasodilation in hypercholesterolemic patients. 47 Importantly, we just recently demonstrated that CETP inhibition with dalcetrapib (formerly JTT-705) increased HDL-C and lowered triglycerides but similarly failed to improve endothelial function. 17 A modest improvement of endothelium-dependent vasodilatation, howewever, was found in the subgroup of patients with low baseline HDL only. Interestingly, all off-target effects of torcetrapib effects became apparent in SHR only, but not in normotensive WKY rats. This suggests that potential deleterious effects of torcetrapib in the vasculature come into play only with a genetic disposition or presence of arterial hypertension. This is in line with early data on the BP Table 3 The endothelial parameters analysed in torcetrapib-treated spontaneously hypertensive rats (SHR-T), placebo spontaneously hypertensive rats (SHR-P), and torcetrapib plus bosentan-treated spontaneously hypertensive rats (SHR-T/B). The BP effects alone, however, do not explain the excess of cardiovascular risk associated with long-term treatment with torcetrapib. However, more than 70% of all patients included in the ILLUMINATE trial had a history of hypertension, while patients with uncontrolled hypertension were excluded from the trial. Nevertheless, hypertension was still the most frequently observed adverse event (18.7% in the torcetrapib vs. 7.5% in the placebo group). 8 The specific off-target effects of torcetrapib described in this study, in particular the sustained and marked impairment of endothelial function, decreased NO-bioavailability and increased ROS production as well as activation of the ET, aldosterone, may at least in part explain the increased mortality associated with torcetrapib treatment in the ILLUMINATE trial. Thus, careful assessment of vascular toxicity is mandatory for the development of other CETP inhibitors. Indeed, as outlined by Pfeffer and Sacks, 48 studies with surrogate endpoints, such as lipids or vascular imaging studies, remain hypothesis generating at best and cannot provide sufficient safety information. Therefore, the question whether CETP inhibition has atheroprotective or proatherogenic role in humans may be answered only when ongoing adequately powered randomized morbidity and mortality trials are completed. Although novel CETP inhibitors such as dalcetrapib and anacetrapib up to now did not appear to have off-target adverse effects on BP and adrenal function, their vascular protective effects are far from established. 49 Since the results of the present study unequivocally demonstrate substantial off-target effects of one of the members of the class of CETP inhibitors unrelated to CETP inhibition, the absence of evidence does not provide evidence of the absence of such off-target effects with the other members of the class. Importantly, BP is unlikely to explain all of the excess morbidity and mortality associated with the use of torcetrapib. Indeed, in the present study, substantial impairment of endothelial function was still present after 3 weeks, a long time after BP already had returned to baseline. As such, the results of the just recently presented DEFINE trial 50 need to be put in perspective, as the absence of a BP increase associated with the use of anacetrapib does not allow to exclude BP independent offtarget effects, endothelial impairment in particular.
Whether and to what degree these unpredicted and potentially deleterious off-target effects are molecule-specific or represent a class effect of CETP inhibitors needs to be ruled out in the clinical development of other CETP inhibitors, such as anacetrapib and dalcetrapib before a large patient population, particularly when at increased cardiovascular risk, is exposed to these compounds.
Supplementary material
Supplementary material is available at European Heart Journal online.
